KatsanosKSpiliopoulosSParaskevopoulosI, et al. Systematic review and meta-analysis of randomized controlled trials of paclitaxel-coated balloon angioplasty in the femoropopliteal arteries: role of paclitaxel dose and bioavailability. J Endovasc Ther. 2016;23:356–370.
2.
CorteseBGranadaJFSchellerB, et al. Drug-coated balloon treatment for lower extremity vascular disease intervention: an international positioning document. Eur Heart J. 2016;37:1096–1103.
3.
AboyansVRiccoJBBartelinkMEL, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by: the European Stroke Organization (ESO), The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39:763–816.
4.
TorselloGStavroulakisKBrodmannM, et al. Three-year sustained clinical efficacy of drug-coated balloon angioplasty in a real-world femoropopliteal cohort. J Endovasc Ther. 2020;27:(5):693–705.
5.
BrodmannMKeirseKScheinertD, et al. Drug-coated balloon treatment for femoropopliteal artery disease: the IN.PACT Global study de novo in-stent restenosis imaging cohort. JACC Cardiovasc Interv. 2017;10:2113–2123.
6.
MicariABrodmannMKeirseK, et al. Drug-coated balloon treatment of femoropopliteal lesions for patients with intermittent claudication and ischemic rest pain: 2-year results from the IN.PACT Global Study. JACC Cardiovasc Interv. 2018;11:945–953.
7.
GeraghtyPJMewissenMWJaffMR, et al. Three-year results of the VIBRANT trial of VIABAHN endoprosthesis versus bare nitinol stent implantation for complex superficial femoral artery occlusive disease. J Vasc Surg. 2013;58:386–395.
8.
AbuRahmaAFAbuRahmaZTScottG, et al. Clinical outcome of drug-coated balloon angioplasty in patients with femoropopliteal disease: a real-world single-center experience. J Vasc Surg. 2019;70:1950–1959.
9.
KrankenbergHTüblerTSixtS, et al. German multicenter real-world registry of stenting for superficial femoral artery disease: clinical results and predictive factors for revascularization. J Endovasc Ther. 2014;21:463–471.
10.
KichikawaKIchihashiSYokoiH, et al. Zilver PTX post-market surveillance study of paclitaxel-eluting stents for treating femoropopliteal artery disease in Japan: 2-year results. Cardiovasc Intervent Radiol. 2019;42:358–364.
11.
IidaOTakaharaMSogaY, et al. 1-Year results of the ZEPHYR Registry (Zilver PTX for the femoral artery and proximal popliteal artery) predictors of restenosis. JACC Cardiovasc Interv. 2015;8:1105–1112.
12.
TranKUlleryBWKretMR, et al. Real-world performance of paclitaxel drug-eluting bare metal stenting (Zilver PTX) for the treatment of femoropopliteal occlusive disease. Ann Vasc Surg. 2017;38:90–98.
13.
ScheinertDGrummtLPiorkowskiM, et al. Novel self-expanding interwoven nitinol stent for complex femoropopliteal lesions: 24-month results of the SUPERA SFA registry. J Endovasc Ther. 2011;18:745–752.
14.
KokkinidisDGJeon-SlaughterHKhaliliH, et al. Adjunctive stent use during endovascular intervention to the femoropopliteal artery with drug coated balloons: Insights from the XLPAD registry. Vasc Med. 2018:23:358–364.
15.
GrayWAGarciaLAAli AminA, et al. Jetstream atherectomy system treatment of femoropopliteal arteries: results of the post-market JET Registry. Cardiovasc Revasc Med. 2018;19(5 pt A):506–511.
16.
ThiemeMBilderlingPVPaetzelC, et al. The 24-month results of the Lutonix Global SFA Registry: worldwide experience with Lutonix drug-coated balloon. JACC Cardiovasc Interv. 2017;10:1682–1690.
17.
SchmidtAPiorkowskiMGörnerH, et al. Drug-coated balloons for complex femoropopliteal lesions: 2-year results of a real-world registry. JACC Cardiovasc Interv. 2016;9:715–724.
18.
TepeGZellerTMoscovicM, et al. Paclitaxel-coated balloon for the treatment of infrainguinal disease: 12-month outcomes in the all-comers cohort of the BIOLUX P-III Global registry. J Endovasc Ther. 2020;27:304–315.
19.
SchroeHHoldenAHGouefficY, et al. Stellarex drug-coated balloon for treatment of femoropopliteal arterial disease—The ILLUMENATE Global Study: 12-month results from a prospective, multicenter, single-arm study. Catheter Cardiovasc Interv. 2018;91:497–504.
20.
MicariACioppaAVadalàG, et al. 2-Year results of paclitaxel-eluting balloons for femoropopliteal artery disease: evidence from a multicenter registry. JACC Cardiovasc Interv. 2013;6:282–289.
21.
PatelMRConteMSCutlipDE, et al. Evaluation and treatment of patients with lower extremity peripheral artery disease: consensus definitions from Peripheral Academic Research Consortium (PARC). J Am Coll Cardiol. 2015;65:931–941.
22.
SerruysPWMoriceMCKappeteinAP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med. 2009;360:961–972.
23.
AdamDJBeardJDClevelandT, et al. Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL): multicentre, randomised controlled trial. Lancet. 2005;366:1925–1934.
24.
Müller-HülsbeckSKeirseKZellerT, et al. Long-term results from the MAJESTIC trial of the Eluvia paclitaxel-eluting stent for femoropopliteal treatment: 3-year follow-up. Cardiovasc Intervent Radiol. 2017;40:1832–1838.
BosiersMScheinertDHendriksJM, et al. Results from the Tack optimized balloon angioplasty (TOBA) study demonstrate the benefits of minimal metal implants for dissection repair after angioplasty. J Vasc Surg. 2016;64:109–116.
27.
SchneiderPALairdJRTepeG, et al. Treatment effect of drug-coated balloons is durable to 3 years in the femoropopliteal arteries: long-term results of the IN.PACT SFA randomized trial. Circ Cardiovasc Interv. 2018;11:e005891.
28.
LairdJASchneiderPAJaffMR, et al. Long-term clinical effectiveness of a drug-coated balloon for the treatment of femoropopliteal lesions: five-year outcomes from the IN.PACT SFA randomized trial. Circ Cardiovasc Interv. 2019;12:e007702.
29.
LairdJRKatzenBTScheinertD, et al. Nitinol stent implantation vs. balloon angioplasty for lesions in the superficial femoral and proximal popliteal arteries of patients with claudication: three-year follow-up from the RESILIENT randomized trial. J Endovasc Ther. 2012;19:1–9.
30.
BunteMCCohenDJJaffMR, et al. Long-term clinical and quality of life outcomes after stenting of femoropopliteal artery stenosis: 3-year results from the STROLL study. Catheter Cardiovasc Interv. 2018;92:106–114.
31.
Rocha-SinghKJBosiersMSchultzG, et al. A single stent strategy in patients with lifestyle limiting claudication: 3-year results from the Durability II trial. Catheter Cardiovasc Interv. 2015;86:164–170.
32.
GarciaLARosenfieldKRMetzgerCD, et al. SUPERB final 3-year outcomes using interwoven nitinol biomimetic Supera stent. Catheter Cardiovasc Interv. 2017;89:1259–1267.
33.
YokoiH.Unique assets of the Zilver Ptx drug eluting stent for treating long complex fempop disease: based on 5-year results of the Japanese post-market surveillance study. Paper presented at: The Veith Symposium; November 13–17, 2019; New York, NY, USA.
34.
GrayWAKeirseKSogaY, et al. A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial. Lancet. 2018;392:1541–1551.
35.
IidaO.Two-year outcomes from the IMPERIAL randomized trial of Eluvia and Zilver PTX. Paper presented at: VIVA 2019; November 4–7, 2019; Las Vegas, NV, USA.
36.
KatsanosKSpiliopoulosSKitrouP, et al. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2018;7:e011245.
FeringaHHBaxJJHoeksS, et al. A prognostic risk index for long-term mortality in patients with peripheral arterial disease. Arch Intern Med. 2007;167:2482–2489.
40.
SartipyFSigvantBLundinF, et al. Ten year mortality in different peripheral arterial disease stages: a population based observational study on outcome. Eur J Vasc Endovasc Surg. 2018;55:529–536.
41.
BeckmanJAWhiteCJ.Paclitaxel-coated balloons and eluting stents: is there a mortality risk in patients with peripheral artery disease?Circulation. 2019;140:1342–1351.
42.
Rocha-SinghKMullinC.Individual patient data meta-analysis of late mortality after paclitaxel containing device exposure. Presented at: The Food and Drug Administration: Circulatory System Devices Panel Meeting, June 19, 2019.
43.
Rocha-SinghK. New data regarding drug-eluting devices: update to the VIVA/NAMSA IPD meta-analysis. Presented at: The TCT 2019; September 25–29, 2019; San Francisco, CA, USA.
44.
SchellerBVukadinovicDJegerR, et al. Survival after coronary revascularization with paclitaxel-coated balloons. J Am Coll Cardiol. 2020;75:1017–1728.
SchneiderPALairdJRDorosG, et al. Mortality not correlated with paclitaxel exposure: an independent patient-level meta-analysis of a drug-coated balloon. J Am Coll Cardiol. 2019;73:2550–2563.
47.
MikiKFujiiKTanakaT, et al. Impact of IVUS-derived vessel size on midterm outcomes after stent implantation in femoropopliteal lesions. J Endovasc Ther. 2020;27:77–85.
48.
PliagasGSaabFStavroulakisK, et al. Intravascular ultrasound imaging versus digital subtraction angiography in patients with peripheral vascular disease. J Invasive Cardiol. 2020;32:99–103.
49.
ShammasNWToreyJTShammasWJ, et al. Intravascular ultrasound assessment and correlation with angiographic findings demonstrating femoropopliteal arterial dissections post atherectomy: results from the iDissection study. J Invasive Cardiol. 2018;30:240–244.
50.
DaviesMGSaadWEPedenEK, et al. Impact of runoff on superficial femoral artery endoluminal interventions for rest pain and tissue loss. J Vasc Surg. 2008;48:619–626.
51.
FeldmanDNArmstrongEJAronowHD, et al. SCAI consensus guidelines for device selection in femoral-popliteal arterial interventions. Catheter Cardiovasc Interv. 2018;92:124–140.
